|

ATR 1072 in Participants With PRKAG2 Syndrome

RECRUITINGPhase 1/2Sponsored by Atrium Therapeutics
Actively Recruiting
PhasePhase 1/2
SponsorAtrium Therapeutics
Started2026-09-14
Est. completion2028-05
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site

Summary

ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Adults 18 to 65 years of age.
2. Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.
3. Clinical manifestations consistent with PRKAG2 Syndrome.
4. Able and willing to comply with study procedures.
5. Able and willing to undergo endomyocardial biopsy procedures (Part A)

Exclusion Criteria:

1. Pregnancy or breastfeeding.
2. Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.
3. NYHA Class IV heart failure or left ventricular ejection fraction \<45%.
4. Recent clinically significant cardiovascular events or procedures.
5. Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods.
6. Any condition that, in the investigator's

Conditions5

Cardiac GlycogenosisCardiomyopathyHeart DiseaseHypertrophicWolff-Parkinson-White Syndrome

Interventions1

Locations1 site

St Luke's Mid American Heart Institute
Michael Nassif, MD816-932-3458michael.nassif@bjc.org

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.